Therapeutic Areas | Pulmonology

AAT Therapy

Product	Primary Uses	Product Description
ARALAST NP [Alpha₁-Proteinase Inhibitor (Human)]	Chronic augmentation therapy in patients having congenital deficiency of A1PI with clinically evident emphysema Please see Important Risk Information Please see full Prescribing Information	Sterile, stable, lyophilized preparation of purified alpha 1-proteinase inhibitor (∝₁Pl), also known as alpha₁-antitrypsin (AAT)

For additional resources, please click here.

ARALAST NP [Alpha₁-Proteinase Inhibitor (Human)]

Alpha-1 antitrypsin deficiency (AATD) is estimated to affect up to 100,000 Americans, but up to 95 percent remain undiagnosed.¹ AATD is not a rare disease but it is rarely diagnosed. The average alpha-1 deficient patient has symptoms for 5.6 years before getting a correct diagnosis.² Since 2003, Baxter has been working to change both the lack of diagnosis and the delay in diagnosis through the development of healthcare professional education and awareness programs, as well as providing a complimentary screening program that has resulted in the testing of over 50,000 individuals across the country.³

Biotherapeutics, a unit of the Baxter’s BioScience business, committed to the alpha-1 community -a commitment that doesn’t end with disease detection. AATmosphere provides support from therapy initiation and care coordination to handling the day-to-day concerns and insurance issues of AATD patients and their families. Enrolling patients in the Aralast NP AATmosphere program puts AATD patients in touch with a team of healthcare and benefits specialists, one-on-one AATmosphere support from Alpha-1 patients, insurance assistance, and current information. AATmosphere is sponsored by Aralast NP augmentation therapy and is easily accessed over the phone or online. The Alpha-1 Security program provides protection against a lapse in insurance coverage.

For members of the medical and the alpha-1 community, BioTherapeutics is with you all of the way.

Indications & Usage

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Important Risk Information

ARALAST NP is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA, since they may experience severe reactions, including anaphylaxis to IgA, which may be present in small quantities in the final drug product.
ARALAST NP is derived from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most common adverse events deemed related to ARALAST NP included: headache (4 of 61 [7%] events) and musculoskeletal discomfort (4 of 61 [7%] events).

Please see full Prescribing Information